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Recently, we demonstrated that RPL5 and RPL11 act
in a mutually dependent manner to inhibit Hdm2 and
stabilize p53 following impaired ribosome biogen-
esis. Given that RPL5 and RPL11 form a preriboso-
mal complex with noncoding 5S ribosomal RNA
(rRNA) and the three have been implicated in the
p53 response, we reasoned they may be part of an
Hdm2-inhibitory complex. Here, we show that small
interfering RNAs directed against 5S rRNA have no
effect on total or nascent levels of the noncoding
rRNA, though they prevent the reported Hdm4 inhibi-
tion of p53. To achieve efficient inhibition of 5S rRNA
synthesis, we targeted TFIIIA, a specific RNA poly-
merase III cofactor, which, like depletion of either
RPL5 or RPL11, did not induce p53. Instead, 5S
rRNA acts in a dependent manner with RPL5 and
RPL11 to inhibit Hdm2 and stabilize p53. Moreover,
depletion of any one of the three components
abolished the binding of the other two to Hdm2, ex-
plaining their common dependence. Finally, we
demonstrate that the RPL5/RPL11/5S rRNA preribo-
somal complex is redirected from assembly into
nascent 60S ribosomes to Hdm2 inhibition as a
consequence of impaired ribosome biogenesis.
Thus, the activation of the Hdm2-inhibitory complex
is not a passive but a regulated event, whose poten-
tial role in tumor suppression has been recently
noted.INTRODUCTION
The integration of cell growth and cell proliferation is essential for
the maintenance of organ size and tissue homeostasis. The rate
of cell growth is in large part determined by the rate of protein
synthesis and hence the availability of translational machinery,particularly ribosomes. Moreover, misregulation of ribosome
biogenesis is associated with extreme forms of aberrant growth,
including anemia and cancer (Barna et al., 2008; Ruggero and
Pandolfi, 2003; Zhang and Lu, 2009). Ribosomes are composed
of a 40S subunit and a 60S subunit, with their biogenesis
requiring the coordinate expression of four distinct noncoding
ribosomal RNAs (rRNAs) and approximately 80 unique ribosomal
proteins (RPs). The 40S subunit is composed of 30 distinct RPs
and a single molecule of 18S rRNA, whereas the 60S subunit
contains 49 unique RPs and single copies of 28S, 5.8S, and 5S
rRNA. Importantly, in contrast to other noncoding rRNAs, which
are transcribed in the nucleolus by RNA polymerase I (Pol I), 5S
rRNA is transcribed in the nucleus by RNA Pol III.
The importance of ribosome biogenesis in coordinating cell
growth and cell division is underscored by the observation
that impairment of this process leads to induction of p53 and
cell-cycle arrest (Fumagalli and Thomas, 2011; Zhang and Lu,
2009). The critical role of this checkpoint in human pathology
was first demonstrated in two hematopoietic disorders, 5q
syndrome and Diamond-Blackfan anemia (DBA) (Draptchinskaia
et al., 1999; Gazda et al., 2008), which are characterized by
monoallelic deletions or hypomorphic mutations of RP genes.
Moreover, patients with these diseases have a high risk of devel-
oping myelodysplasia and a wide range of distinct neoplasias
later in life, including acute myeloid leukemia, colon carcinoma,
and osteogenic sarcoma (Vlachos et al., 2012). The induction
of p53 was previously shown to be mediated by the binding
and inhibition of human double minute 2 (Hdm2) by a subset of
RPs, particularly RPS7, RPL5, RPL11, and RPL23 (Zhang and
Lu, 2009). Hdm2 is an E3 ubiquitin ligase, which regulates the
proteasome-dependent degradation of p53 and is the main
regulator of the tumor suppressor. The complexity of this regula-
tory circuit is further accentuated by the fact that Hdm2 is a p53
transcriptional target, apparently to ensure p53 downregula-
tion nce an insult has been managed (Barak et al., 1993;
Wu et al., 1993).
Previously, we demonstrated that either deletion of RP genes
or depletion of their transcripts led to the impairment of ribosome
biogenesis and the induction of p53 in a manner dependent on
the binding of RPL11 to Hdm2. Moreover, codepletion ofCell Reports 4, 87–98, July 11, 2013 ª2013 The Authors 87
RPL11 was sufficient to suppress the rise in p53 and relieve the
cell-cycle block (Fumagalli et al., 2009). Given the role of RPS7,
RPL5, and RPL23 in mediating this effect, one may have ex-
pected that depleting cells of RPL11 would not have been suffi-
cient to relieve the p53 response. This conundrum led us to the
finding that only RPL11 and RPL5, in a mutually dependent
manner, are required for p53 induction following disruption of
ribosome biogenesis (Fumagalli et al., 2012). Importantly, recent
studies demonstrate that this checkpoint may also act as a
tumor suppressor in B cell lymphomas overexpressing c-Myc
under the control of the immunoglobulin heavy chain promoter
and enhancer (Em-Myc) (Macias et al., 2010). In part, c-Myc pro-
motes tumorigenesis in this setting by inducing the upregulation
of ribosome biogenesis. However, when a cancer-associated
single point mutation within the zinc-finger domain of Hdm2,
which abolishes its binding to RPL11 and RPL5 but not the alter-
native reading frame, was knocked into thewild-type locus of the
mouse Mdm2 gene of Em-Myc mice, they succumbed much
more rapidly to B cell lymphoma than control Em-Myc mice
(Macias et al., 2010). Thus, this regulatory mechanism
appears to constitute a highly sensitive surveillance system to
monitor either impairment or hyperactivation of ribosome
biogenesis.
In yeast, orthologs of RPL11 and RPL5 form a complex with 5S
rRNA prior to their incorporation into the nascent 90S proces-
some, a step mediated by two assembly factors, Rpf2 and
Rrs1 (Zhang et al., 2007). It was first shown by Marechal et al.
that immune precipitates of Hdm2 contained both RPL5 and
5S rRNA (Marechal et al., 1994). In more recent studies, Horn
and Vousden demonstrated that overexpression of either
RPL11 or RPL5 alone was sufficient to suppress Hdm2 and
induce p53. However, Hdm2 inhibition was more robust when
both RPs were coexpressed, an effect mediated by RPL11’s
ability to recruit RPL5 indirectly to Hdm2 via 5S rRNA (Horn
and Vousden, 2008). Together these results led us to predict
that in higher eukaryotes, 5S rRNA is part of a complex contain-
ing RPL11 and RPL5, which acts to suppress Hdm2 and in-
crease p53, following impairment or hyperactivation of ribosome
biogenesis (Fumagalli et al., 2012). However, Li and Gu recently
showed that 5S rRNA is required for Hdm4-mediated inhibition
of p53 (Li and Gu, 2011). Hdm4 is highly homologous to Hdm2
but is devoid of ligase activity and instead directly binds to p53
to inhibit its transactivation function (Marine and Jochemsen,
2004). Interestingly, the form of 5S rRNA associated with
Hdm4 was reported to be the immature form, having two addi-
tional uridines at the 30 terminus (Li and Gu, 2011). This form of
5S rRNA does not interact with RPL5, which only binds the
more abundant mature form of 5S rRNA (Steitz et al., 1988; Ci-
ganda and Williams, 2011). This finding raised the possibility
that the seemingly contradictory role of 5S rRNA in mediating
p53 function may be due to the immature form stabilizing
Hdm4, whereas the mature form inhibits Hdm2. The significance
of elucidating the molecular mechanisms mediating these two
responses is underscored by the importance of p53, Hdm2,
andHdm4, which aremisregulated in over 50%of human tumors
(Bond et al., 2004; Toledo and Wahl, 2006).
Here, we set out to assess the role of 5S rRNA inmediating p53
stability in cells in which ribosome biogenesis is impaired. We88 Cell Reports 4, 87–98, July 11, 2013 ª2013 The Authorsfound that directly targeting 5S rRNA with a specific small
interfering RNA (siRNA) not only had no effect on total ribosome
production (Li and Gu, 2011) but also did not affect nascent 5S
rRNA synthesis. We then turned to the potential of depleting cells
of TFIIIA, a Pol III cofactor specifically required for 5S rRNA
transcription (Engelke et al., 1980; Shastry et al., 1984). Such
treatment effectively blocked 5S rRNA biogenesis and 60S
subunit production. Inhibition of this process impaired 60S ribo-
some biogenesis at the same step as depletion of either RPL5 or
RPL11. Contrary to earlier findings, all three components are
jointly dependent on one another to bind Hdm2 and inhibit p53
degradation in response to impaired ribosome biogenesis.
Importantly, we demonstrate that despite the large abundance
of the mature RPL5/5S rRNA complex, it is apparently the
nascent preribosomal RPL5/RPL11/5S rRNA complex that is
redirected from 60S ribosome biogenesis to Hdm2 inhibition
upon disruption of ribosome biogenesis and that formation of
the complex does not require p53 or Hdm2. The results under-
score the importance of a critical regulatory circuit mediated
by an apparent nascent RPL5/RPL11/5S rRNA preribosomal
complex in controlling p53 levels and cell-cycle progression.
RESULTS
Mature 5S rRNA Binds Both Hdm2 and Hdm4
To examine the role of 5S rRNA on the regulation of p53, we
treated U2 OS cells with either a nonsilencing siRNA (si-NS) or
one directed against 5S rRNA (si-5S). We found that treatment
of U2 OS cells with the si-5S, as compared to those treated
with the si-NS, leads to the reduction of Hdm4 protein and the
activation of p53-dependent transcription, as judged by the
induction of p21 and Hdm2 (Figure 1A), consistent with the find-
ings of Li and Gu (2011). If not a component of the RPL5/RPL11
Hdm2 inhibitory complex, then we would have expected deple-
tion of 5S rRNA to impair 60S ribosome biogenesis and induce
p53. It is known that the more abundant mature form of 5S
rRNA interacts with Hdm2 (Marechal et al., 1994), whereas it is
the immature form that is reported to mediate Hdm4 inhibition
of p53 (Li and Gu, 2011). This raised the possibility that the
less abundant immature form, potentially the nascent form, is
selectively lost by si-5S treatment, leading to the observed acti-
vation of p53 (Figure 1A). Unexpectedly, the cloning and
sequencing of the 5S rRNA associated with either Hdm4 or
Hdm2 (Experimental Procedures) revealed that both repre-
sented the 119-residue mature form of 5S rRNA, with no clones
representing the larger immature 5S rRNA species (Figure 1B).
Thus, the effects of si-5S siRNA treatment on the activation of
p53 do not appear to be attributed to the selective loss of the
less abundant immature species of 5S rRNA.
Given the findings above, we examined the effect of si-5S
treatment on ribosome biogenesis by analyzing total rRNA levels
by ethidium bromide (EB) staining and newly synthesized rRNA
by pulse labeling with 3H-uridine (Fumagalli et al., 2009). As 5S
rRNA is an essential component of the 60S ribosome, suppress-
ing its expression should also affect 28S and 5.8S rRNAprocess-
ing but not that of 18S rRNA (Dechampesme et al., 1999; Zhang
et al., 2007). The EB-stained polyacrylamide gel shows that si-5S
depletion, as compared to si-NS, had no effect on total levels of
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Figure 2. Effect of TFIIIA Depletion on RNA Pol-III-Dependent
Transcription
(A) TFIIIA mRNA levels in US OS cells transfected with si-NS or si-TF were
evaluated by quantitative real-time PCR. Bar graphs show the mean ±SEM of
three samples.
(B) EB-stained TBE-urea polyacrylamide gel (left) and autoradiogram of a
northern blot (right) showing newly synthesized 3H-uridine-labeled 5S rRNA in
U2 OS cells transfected for 24, 48, and 72 hr with si-NS or si-TF; 2 mg of total
cellular RNA per lane.
(C) Quantitative real-time PCR quantification of Leu- and Tyr-tRNA precursors
in U2 OS cells transfected as described in (A).
Bar graphs show the mean value ±SEM of three samples. See also Figure S1.
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Figure 1. Effect of 5S rRNA-Targeted siRNA on Ribosome Biogen-
esis
(A) Western blot analysis of expression levels of Hdm4, p53, p21 and Hdm2
and the loading control b-actin in U2 OS cells transfected for 72 hr with si-NS
(NS) or si-5S (5S).
(B) 5S rRNA that coimmunoprecipitated with Hdm2 or HA-tagged Hdm4 was
cloned and sequenced (Experimental Procedures).
(C) EB-stained TBE-urea polyacrylamide gel (left) and autoradiogram of a
northern blot (right) of newly synthesized 3H-uridine-labeled 5S rRNA in U2 OS
cells transfected with si-NS or si-5S; 2 mg of total cellular RNA per lane.
(D) EB-stained agarose gel (left) and autoradiogram of a northern blot (right)
of total cellular RNA from si-NS or si-5S transfected U2 OS cells labeled with
3H -uridine for 1 hr and then chased for 4 hr in nonlabeled uridine-containing
medium; 1 mg of total cellular RNA per lane.5S rRNA or on 5.8S rRNA (Figure 1C), consistent with the find-
ings of Li and Gu (2011). Moreover, analysis of the larger rRNA
species on agarose gels showed no apparent differences in
either 28S or 18S rRNA levels (Figure 1D). However, si-5S treat-
ment also had no impact on the incorporation of 3H-uridine into
nascent 5S rRNA or into 5.8S and 28S rRNA (Figures 1C and D),
which is consistent with the absence of an impaired ribosome
biogenesis-induced p53 response, despite the ability of such
treatment to repress Hdm4 (Figure 1A) (Li and Gu, 2011). Thus,
si-5S treatment leads to loss of Hdm4 and p53 activation butdoes so independent of impairing 5S rRNA production or
nascent ribosome biogenesis.
Depletion of TFIIIA Selectively Impairs 5S rRNA
Synthesis
Given the limitations of an siRNA approach in depleting either
total or nascent 5S rRNA, we turned to an alternative strategy,
depletion of Pol III cofactor TFIIIA/GTF3A, which is specifically
required for 5S rRNA transcription. Treatment of U2 OS cells
with an siRNA against TFIIIA (si-TF) effectively reduced its
messenger RNA (mRNA) levels at each time point examined
up to 72 hr posttransfection, as measured by quantitative
real-time PCR (Figure 2A). To determine the extent to which
si-TF treatment affected mature and nascent pools of 5S
rRNA, we followed a similar protocol to that described above
(Figures 1C and 1D). As in the case of si-5S treatment, the re-
sults of EB staining show that TFIIIA depletion had no observ-
able effect on total levels of 5S rRNA or 5.8S rRNA up toCell Reports 4, 87–98, July 11, 2013 ª2013 The Authors 89
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Figure 3. Effect of TFIIIA Depletion on Ribo-
some Biogenesis
(A) Pre-rRNA processing pathway in mammals.
(B) EB-stained agarose gel (left) and autoradio-
gram of a northern blot (right) of 3H-uridine-labeled
RNA (1 hr pulse and 4 hr chase) from U2 OS cells
72 hr after the transfection of si-NS or si-TF; 1 mg of
total cellular RNA per lane.
(C) EB stained agarose gel (left) and northern blot
(right) of total RNA extracted from U2 OS cells
72 hr after transfection with siRNAs specific for
si-NS (NS), si-TF (TF), RPL5 (L5), or RPL11 (L11).
Northern blot hybridized with a probe directed
against ITS2 (internal transcribed spacer 2) of
precursor rRNA: 1 mg of total cellular RNA per lane.
(D) Polysome profiles of extracts from U2 OS cells
transfected with si-NS or si-TF.72 hr posttransfection (Figure 2B). However, contrary to si-NS-
or si-5S-treated cells, those treated with si-TF showed a clear
reduction in newly synthesized 5S rRNA, as measured by auto-
radiography, an effect detected as early as 48 hr posttransfec-
tion (Figure 2B). Consistent with 5S rRNA being an essential
component of the 60S ribosome, TFIIIA depletion also sup-
pressed nascent 5.8S rRNA production (Figure 2B). That this
effect is specific for transcription of 5S rRNA, and no other
Pol III transcriptional targets, is shown by the fact that si-TF
treatment did not appear to inhibit Pol-III-dependent transcrip-
tion of total transfer RNA (tRNA) (Figure 2B) or that of leucyl- or
tyrosyl-tRNA (Figure 2C). It should be noted that such treatment
also led to a reduction in Hdm4 levels (Figure S1), consistent
with the requirement of nascent 5S rRNA for its stability.
Thus, depletion of TFIIIA does not affect total 5S rRNA
levels but effectively suppresses the production of nascent
5S rRNA.90 Cell Reports 4, 87–98, July 11, 2013 ª2013 The AuthorsDepletion of TFIIIA Impairs
Ribosome Processing
In yeast, mutants of 5S rRNA, as with loss
of either RPL5 or RPL11, exhibit impaired
processing of 27SB pre-rRNA into a
mature 25S rRNA and 5.8S rRNA, retard-
ing 60S ribosome production (Decham-
pesme et al., 1999). Likewise, disruption
of the incorporation of the RPL5/RPL11/
5S rRNA preformed complex into the
90S processome leads to the accumula-
tion of the same 27SB pre-rRNA (Zhang
et al., 2007). The orthologous steps in
mammalian rRNA processing are de-
picted in Figure 3A. To determine the
step at which depletion of TFIIIA inhibited
human ribosome biogenesis, we exam-
ined rRNA processing in si-TF or si-NS-
treated cells pulse-labeled for 1 hr with
3H-uridine, followed by a 4 hr chase with
unlabeled uridine. The results revealed a
reduction in 28S rRNA production and
the accumulation of both the 47/45S
and 36/32S rRNA precursor but no effecton 18S rRNA production (Figure 3B). To ensure that this rRNA
species represented the 36S/32S rRNA precursor and to deter-
mine whether depletion of nascent 5S rRNA impaired the same
step of rRNA processing as that induced by depletion of human
RPL5 or RPL11, northern blots were probed for the internal tran-
scribed spacer 2 (ITS2) sequence, which resides between the
mature 5.8S and 28S rRNA sequence in the 47S rRNA precursor
(Figure 3A). In all cases, depletion of any of the three 60S compo-
nents led to the accumulation of the same 36/32S precursor
rRNA in U2 OS cells as compared to cells treated with the
si-NS (Figure 3C). Taken together, these results demonstrate
that depletion of TFIIIA, as well as either RPL5 or RPL11, impairs
ribosome biogenesis at a step that is analogous to that in yeast,
at which the RPL5/RPL11/5S rRNA complex is assembled into
the 90S processome. Consistent with these findings, analysis
of polysome profiles demonstrated that depletion of TFIIIA led
to a loss of native 60S ribosomes and an increase in native
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Figure 4. Effect of TFIIIA Depletion on the Stabilization of p53
(A) U2 OS, HCT 116, and A549 cells were transfected for 72 hr with si-NS or
si-TF, total RNA was extracted, and TFIIIA mRNA levels were evaluated by
quantitative real-time PCR analysis. Bar graphs show the mean ±SEM of three
independent experiments.
(B) Western blot analysis showing expression levels of p53, p21, and Hdm2
and the loading control b-actin in U2 OS, A549, and HCT 116 cells 72 hr after
transfection with si-NS, si-TF, or an siRNA specific for POLR1A (Pol I).
(C) Cell-cycle phase distribution in U2 OS cells transfected with the indicated
siRNAs.
(D) Western blot analyses showing expression levels of p53, p21, and Hdm2
and the loading control b-actin in U2 OS cells transfected for 72 hr with
individual or combined siRNAs to NS, TFIIIA, RPL5, RPL11, or Pol I.
See also Figures S2 and S3.40S ribosomes (Figure 3D). In addition, the reduction in the
amount of 60S ribosomal subunits relative to the amount of
40S ribosomal subunits led to the increased formation of 43S
preinitiation complexes, visualized as half-mer polyribosomes,
observed as a pronounced shoulder on the right side of the
80S monosome and polysomal peaks (Figure 3D). We have
recently reported similar results for the depletion of RPL5 and
RPL11 (Fumagalli et al., 2012), consistent with depletion of TFIIIA
affecting the same step of 60S ribosome biogenesis as loss of
RPL5 or RPL11.
RPL5, RPL11, and 5S rRNA Are Mutually Dependent on
Each Other for p53 Response following Impaired
Ribosome Biogenesis
Although depletion of either RPL5 or RPL11 impairs ribosome
biogenesis, they are mutually dependent on one another to
inhibit Hdm2 and induce p53 (Fumagalli et al., 2012). To deter-
mine whether depletion of nascent 5S rRNA exerts a similar
response or whether instead its depletion leads to the induction
of p53, we treated U2 OS cells, as well as HCT116 and A549
cells, with si-NS, si-Polr1a (the catalytic subunit of the Pol I
complex), and si-TF alone or si-TF in combination with si-
Polr1a. We have previously shown that silencing of Polr1a
induced p53 in response to inhibition rRNA transcription (Donati
et al., 2011). The results show that in all cases, TFIIIA mRNA
levels were reduced by R90% of those observed in si-NS-
treated cells (Figure 4A). Such treatment had little to no effect
on basal levels of p53 or on the two downstream target genes
p21 and Hdm2, whereas depletion of TFIIIA completely reversed
the effects on all three responses elicited by Polr1a depletion
(Figure 4B). Moreover, consistent with the effects observed on
p53 and p21, the depletion of Polr1a led to the accumulation
of cells in G1, an effect that was relieved by the codepletion of
TFIIIA (Figure 4C). To ensure these effects were specific for
TFIIIA depletion, we analyzed two additional siRNAs, one that
effectively lowered the levels of the cognate transcript to the
same level as the original siRNA and one that had little effect
(Figure S2A). The data show that only the two that reduced TFIIIA
mRNA levels suppressed the induction of p53, Hdm2, and p21
when codepleted with Polr1a (Figure S2B). Moreover, the
suppression of the p53 response by codepletion of TFIIIA was
not confined to Polr1a, as the same effect was observed by
codepletion of TFIIIA with RPS6 or RPL7a, whose individual
depletion leads to disruption of 40S and 60S ribosome biogen-
esis, respectively (Figure S3A). This was also the case for the
induction of p53 and p21 by chemotherapeutic agents known
to inhibit ribosome biogenesis: actinomycin D (Perry, 1963)
and 5-fluorouracil (Wilkinson and Pitot, 1973) (Figure S3B).
Finally, the ability of TFIIIA to suppress the induction of p53, as
well as p21 and Hdm2, by Polr1a depletion was not further
enhanced by codepletion of either RPL5 or RPL11 (Figure 4D).
These findings indicate that all three components are mutually
dependent on one another for inhibition of Hdm2.
5S rRNA, RPL5, and RPL11 Binding to Hdm2 Is Mutually
Dependent
The results above support a model where impairment of ribo-
some biogenesis leads to the inhibition of Hdm2 and theCell Reports 4, 87–98, July 11, 2013 ª2013 The Authors 91
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Figure 5. RPL5, RPL11, and 5S rRNA Bind-
ing to Hdm2
(A) Western blot analyses showing expression
levels of Hdm2, RPL5, RPL11, RPL36a, and
b-actin protein from U2 OS cells transfected with
control si-NS, si-TF, or siRNAs specific for RPL5
and RPL11 in combination with Pol I siRNA, before
(left) and after (right) ultracentrifugation.
(B) U2 OS cells were transfected for 48 hr with
either si-NS or Pol I siRNA in combination with
siRNA targeted to TFIIIA, RPL5, or RPL11 and then
harvested for immunoprecipitation analysis.
Western blot analyses show the expression levels
of Hdm2 in the postribosomal lysates (INPUT) and
of Hdm2, p53, RPL5, and RPL11 immunoprecipi-
tated from cell lysates with anti-Hdm2 rabbit
antibody (IP HDM2) or rabbit immunoglobulin
G control (IP IgG).
(C) Quantification by quantitative real-time PCR of
5S rRNA associated with Hdm2 or IgG immuno-
precipitated complexes, prepared as described in
(B). Bar graphs show the mean value ±SEM of
three samples.
(D) U2 OS cells were first transfected for 24 hr with
si-NS or Pol I siRNA in combination with NS, TFIIA,
RPL5, or RPL11 siRNAs and then transfected for
an additional 24 hr with an HA-tagged Hdm2
expression plasmid before harvesting for coim-
munoprecipitation analysis. Western blot analyses
show expression levels of total and exogenous
HA-tagged MDM2 in the initial lysates (INPUT) and
levels of HA-Hdm2, p53, RPL5, and RPL11
immunoprecipitated with an HA antibody (12CA5)
from postribosomal cell lysates. Normal growing,
nontransfected U2 OS cells were used as a control
(Ctrl).
(E) Quantification by quantitative real-time PCR of
5S rRNA immunoprecipitated with an HA antibody
from U2 OS cells transfected as described in (D).
Bar graphs show the mean value ±SEM of three
samples.stabilization of p53 in a mutually dependent manner by RPL5,
RPL11, and 5S rRNA. As it has been shown that exogenously
expressed RPL5 and RPL11 can bind independently to Hdm2
(Bhat et al., 2004; Dai and Lu, 2004; Horn and Vousden, 2007;
Lohrum et al., 2003), we reasoned that depletion of any one
member should not affect the binding of the others. To test this
hypothesis, we immunoprecipitated Hdm2 from cells treated
for 48 hr with si-Polr1a alone or together with si-RPL5, si-RPL11,
or si-TF and scored for the association of each of the three com-
ponents with Hdm2. Prior to immunoprecipitation, cell lysates
were subjected to high-speed ultracentrifugation to clear mature
ribosomes, thus minimizing nonspecific interactions of mature
ribosomes during the coimmunoprecipitation (Experimental
Procedures). This step does not alter the levels of Hdm2
compared to those of the total lysates, employing b-actin as a
control, whereas the majority of ribosomal proteins are cleared
from the lysate (Figure 5A). The Hdm2 immunoprecipitates of
the postribosomal lysates were then divided in two fractions,
which were used for either protein or RNA analysis. Parallel92 Cell Reports 4, 87–98, July 11, 2013 ª2013 The Authorsanalyses of these immunoprecipitates by western blot or quanti-
tative real-time PCR revealed the presence of RPL5, RPL11, and
5S rRNA (Figures 5B and 5C, respectively). Unexpectedly,
depletion of RPL5, RPL11, or TFIIIA abolished the interaction
of the other two components with Hdm2 (Figures 5A and 5B),
arguing that their binding to Hdm2 is mutually dependent.
Although depletion of RPL5, RPL11, or 5S rRNA abolished the
interaction of the other two components with Hdm2, such treat-
ment also reduced the levels of the E3 ligase (Figures 5A and 5B),
consistent with Hdm2 being a p53 target. Given the findings of
others (Bhat et al., 2004; Dai and Lu, 2004; Horn and Vousden,
2007; Lohrum et al., 2003), this raised the possibility that the
reduced amount of Hdm2 recovered by immunoprecipitation
may in part explain our inability to detect coimmunoprecipitated
RPL5, RPL11, and 5S rRNA. To address this issue, 24 hr
following transfection of si-Polr1a alone or together with
si-RPL5, si- RPL11, or si-TF, cells were retransfected with a
plasmid encoding a hemagglutinin (HA)-tagged Hdm2 (Experi-
mental Procedures). The transcription of Hdm2 from this plasmid
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Figure 6. Formation of the RPL5/RPL11/5S rRNA Complex Is
Independent of 60S Ribosome Biogenesis and Hdm2
(A) EB-stained agarose gel (left) and northern blot (right) of total RNA extracted
from U2 OS cells 72 hr after transfection with NS-, hRRS1-, or BXDC1-specific
siRNA. The northern blot was hybridized with a probe directed against ITS2 of
precursor rRNA (Figure 3A); 1 mg of total cellular RNA per lane.
(B)Western blot analyses showingexpression levels of p53, p21,Hdm2,and the
loading control b-actin from U2 OS cells transfected with NS, hRRS1, BXDC1,
and TFIIIA siRNAs, alone and in combination with Pol-I-targeted siRNA.
(C) Mdm2/p53 knockout MEFs were transfected for 24 hr with FLAG-tagged
RPL5 or RPL11 and treated for 5 hr with 5 ng/ml actinomycin D before
harvesting. Postribosomal lysates from control (Ctrl) and FLAG-expressing
MEFs were immunoprecipitated with a FLAG antibody. Western blot analyses
show FLAG-tagged proteins in the postribosomal lysates (INPUT) and both
endogenous and exogenous RPL5 and RPL11 proteins that coimmunopreci-
pitated with the FLAG antibody. Light and dark exposure times are shown for
the RPL11 blot.
(D) Quantification by quantitative real-time PCR of 5S rRNA that immunopre-
cipitated with FLAG antibody from the postribosomal fraction of MDM2/p53
knockout MEFs transfected and treated as described in (C).
See also Figure S4.is p53 independent, and the protein is produced in much higher
amounts than its endogenous counterpart, which was undetect-
able in the exposure shown (Figure 5D). After an additional 24 hr,
postribosomal lysates were prepared, exogenous HA-Hdm2
was immunoprecipitated, and the interacting proteins and
rRNAs were analyzed by western blot or quantitative real-time
PCR, respectively. Under these conditions, the expression of
HA-tagged Hdm2 was relatively equal as was its immunoprecip-
itation (Figure 5D). The results show that only in cells treated with
si-Polr1a alone were RPL5, RPL11, and 5S rRNA efficiently
coimmunoprecipitated with HA-tagged Hdm2 (Figures 5D and
5E, respectively). Thus, the interdependence of endogenous
RPL5, RPL11, and 5S rRNA in binding and suppressing Hdm2
appears to be independent of the levels of the E3 ligase.
RPL5, RPL11, and 5S rRNA Are Redirected to Hdm2
following Impaired Ribosome Biogenesis
That the depletion of nascent rRNA, but not total 5S rRNA, was
associated with suppressing the induction of p53 following
impaired ribosome biogenesis (Figures 2B and 4B) suggests
that it is the nascent RPL5/RPL11/5S rRNA precursor complex
that is redirected from 60S ribosome biogenesis to the inhibition
of Hdm2. In yeast, Rrs1 and Rpf2 are required to load the RPL5/
RPL11/5S rRNA precursor complex into the 90S processome
(Zhang et al., 2007). The apparent human orthologs of the yeast
proteins are hRrs1 and Bxdc1 (Gambe et al., 2009; Hirano et al.,
2009). If the nascent RPL5/RPL11/5S rRNA precursor complex
is normally loaded onto the 90S processome by hRrs1 and
Bxdc1, then one would predict that their depletion would impair
ribosome biogenesis at the same stage as loss of RPL5, RPL11,
or TFIIIA, but would not be required for Hdm2 inhibition. Consis-
tent with this prediction, depletion of either hRrs1 or Bxdc1 in U2
OS cells, as judged by quantitative real-time PCRof their respec-
tive mRNAs (Figure S4), impeded the processing of the 36S/32S
rRNA precursor as measured with a probe to ITS2 (Figure 6A),
similar to that seen for cells depleted of RPL5, RPL11, or 5S
rRNA (Figure 3C), supporting a conserved function for hRrs1
and Bxdc1 in ribosome biogenesis. To determine whether they
are implicated in the p53 response induced by impaired
ribosome biogenesis, we transfected cells with si-hRrs1 or
si-Bxdc1 alone or in combination with si-Polr1a, employing si-
TF as a positive control. The results show that, unlike the loss
of RPL5, RPL11, or TFIIIA, depletion of either hRrs1 or Bxdc1
led to the induction of p53 and further augmented the response
induced by depletion of Polr1a (Figure 6B). This would suggest
that hRrs1 or Bxdc1 lie at, or downstream of, the regulatory bifur-
cation point that mediates the targeting of a RPL5/RPL11/5S
rRNA precursor complex to inhibition of Hdm2.
The results above also suggest that binding of such a precur-
sor complex to Hdm2 would be independent of Hdm2 availabil-
ity, as its overexpression in the absence of impaired ribosome
biogenesis does not lead to the recruitment of the RPL5,
RPL11, or 5S rRNA (Figures 5D and 5E). To determine whether
all three components interact independent of Hdm2, we
took advantage of mouse embryo fibroblasts (MEFs) from
Mdm2//p53/-deficient mice (Montes de Oca Luna et al.,
1995) treated with a low dose of actinomycin D to impair ribo-
some biogenesis. Our initial efforts to immunoprecipitateCell Reports 4, 87–98, July 11, 2013 ª2013 The Authors 93
Figure 7. Model of p53 Regulation
See text for explanation.endogenous RPL5 and RPL11 after high-speed centrifugation to
remove mature ribosomes failed (data not shown), potentially
due to low levels of the endogenous RPL5/RPL11/5S rRNA com-
plex. Therefore, we ectopically expressed FLAG-tagged RPL5 or
RPL11 in Mdm2//p53/ MEFs as reporters. Despite the fact
that we expressed a great deal more of FLAG-tagged RPL5
than FLAG-tagged RPL11 (Figure 6C, top), we clearly detect
endogenous RPL5 in a coimmunoprecipitation (coIP) with the
exogenous FLAG-RPL11 and endogenous RPL11 in a coIP
with the FLAG-RPL5 (Figure 6C, bottom). Moreover, these sig-
nals were absent in untransfected control cells (Figure 6C). In
parallel, as compared to untransfected Mdm2//p53/
MEFs, we found a 610-fold and a 35-fold enrichment of 5S
rRNA associated with FLAG-RPL5 and FLAG-RPL11, respec-
tively (Figure 6D). The 20-fold enrichment in 5S rRNA observed
in association with FLAG-RPL5, compared to the FLAG-
RPL11, may reflect its higher expression and the ability of
RPL5 and 5S rRNA to form an abundant complex independent
of the 60S ribosome (Steitz et al., 1988). These results support
the model that RPL5, RPL11, and 5S rRNA form a complex inde-
pendent of Hdm2. Taken together, these findings suggest that
upon impairment of ribosome biogenesis, the nascent RPL5/
RPL11/5S rRNA precursor complex is redirected to Hdm2 rather
than into nascent 60S ribosomes (Figure 7).
DISCUSSION
We recently demonstrated that the role of many RPs, including
RPS7 and RPL23, previously implicated in the inhibition of
Hdm2 and the induction of p53, may potentially be attributed
to a general global inhibition of protein synthesis rather than spe-
cific inhibition of Hdm2 (Fumagalli et al., 2012). The exceptions
appear to be RPL5 and RPL11, which are mutually dependent
on one another to elicit this response (Fumagalli et al., 2012), a
finding recently substantiated by others (Bursac et al., 2012).
Moreover, RPL5 and RPL11 have been implicated in a c-Myc-
induced Hdm2-dependent tumor suppressor checkpoint
(Macias et al., 2010). Our results suggest a central role for 5S
rRNA in this complex. Indeed, given the earlier findings that
implicated 5S rRNA as an RPL5/RPL11 interacting partner in94 Cell Reports 4, 87–98, July 11, 2013 ª2013 The Authorsregulating Hdm2 (Horn and Vousden, 2008; Marechal et al.,
1994), we reasoned that 5S rRNA would also be required to
induce p53 following impairment of ribosome biogenesis
(Fumagalli et al., 2012). Although this appears to be the case,
the recent studies presented by Li and Gu and those carried
out here demonstrate that 5S rRNA is also a positive regulator
of Hdm4 (Li and Gu, 2011). Interestingly, 5S rRNA levels are
not affected by siRNA treatment (Li and Gu, 2011; Figure 1),
raising the possibility that si-5S rRNA may act by disrupting
the interaction of Hdm4 with a specific 5S rRNA subpopulation.
Moreover, in contrast to Li and Gu, our results would argue that
this effect, like that of impaired ribosome biogenesis, ismediated
predominantly by the mature form of 5S rRNA (Figure 1B).
Disruption of ribosome biogenesis leads to rapid degradation
of Hdm4 by Hdm2, releasing the block on p53, as does the bind-
ing of an apparent RPL5/RPL11/5S rRNA complex to Hdm2, the
two steps leading to the concerted activation of p53 (Li and Gu,
2011). The role of 5S rRNA in mediating Hdm4 inhibition of p53
would be an attractive alternative mechanism to link rates of
ribosome biogenesis to cell-cycle progression. However, 5S
rRNA exists in an abundant extraribosomal population (Knight
and Darnell, 1967), with levels reported to be twice those of
the other noncoding rRNAs (Gottlieb and Steitz, 1989), suggest-
ing it may not be a sensitive sensor. Instead, this role appears to
reside in the RPL5/RPL11/5S rRNA complex, which may be
consumed in exponentially growing cells into nascent 60S ribo-
somes, leading to a potential coordinate decrease in p53 levels
(Donati et al., 2011). As cells become confluent, p53 levels
most likely rise in an RPL5/RPL11/5S rRNA-complex-dependent
manner (Bhat et al., 2004). Given that levels of RPL5 in the nucle-
olus, like 5S rRNA, are in excess compared to all other RPs
(Phillips and McConkey, 1976) might suggest that the rate-
limiting step would be RPL11 availability; however, ectopic
expression of RPL11 without coexpression of RPL5 was not as
robust in inhibiting Hdm2 as expression of the two RPs together
(Horn and Vousden, 2008). Our findings suggest that it is more
likely that the inhibitory step is a regulated event leading to redi-
rection of a nascent RPL5/RPL11/5S rRNA complex from the
60S ribosome to Hdm2 (Figure 7). It will be important to discern
in future studies whether the Hdm4/5S rRNA complex is a target
of the Hdm2/RPL5/RPL11/5S rRNA complex under impaired
ribosome biogenesis or whether it has a more complex role in
a feedback regulatory circuit that is mediated by the state of
nascent ribosome biogenesis.
Recent studies have also implied a critical role for RPL11 in
independently controlling the levels of p53 through inhibition of
Hdm2 (Sasaki et al., 2011). Here, the protein interacting with
carboxyl terminus 1 (PICT1) of the tumor suppressor PTEN has
been implicated as a negative regulator of RPL11 (Sasaki
et al., 2011). Sasaki and coworkers demonstrated that colorectal
and esophageal tumors, which are p53 wild-type and express
low levels of PICT1, have a significantly better prognosis (Sasaki
et al., 2011). Moreover, they demonstrated that inducible dele-
tion of the floxed PICT1 gene in MEFs led to induction of p53
and apoptosis. They show this effect was mediated by the
release of RPL11, a PICT1 binding protein, from the nucleolus
to the nucleoplasm, where it can bind and inhibit Hdm2. Consis-
tent with these findings, they observed that siRNA depletion of
RPL11 suppressed p53 that was induced by loss of PICT1.
However, in contrast with our findings on impaired ribosome
biogenesis (Fumagalli et al., 2012), they found these effects
were independent of RPL5 (Sasaki et al., 2011). This finding is
consistent with the failure of RPL5 to be released from the nucle-
olus following depletion of PICT1. We find that PICT1 shares a
significant degree of homology with the yeast 60S processing
enzyme Nop53 (Thomson and Tollervey, 2005), and in prelimi-
nary studies its depletion appears to selectively impede nascent
60S ribosomal biogenesis (A. Gentilella, G.D., and G.T., unpub-
lished data). Thus, we would have predicted that the induction
of p53 by loss of PICT1 would have been dependent on the
RPL5/RPL11/5S rRNA complex. It will be of interest to determine
the relationship of PICT1 with RPL5, RPL11, and 5S rRNA and
the mechanism through which they interact with one another to
regulate Hdm2.
Earlier, we demonstrated that regulation of 40S and 60S
ribosome biogenesis led to the induction of p53 by an RPL5-
and RPL11-dependent mechanism (Fumagalli et al., 2009,
2012). However, in the case of impaired 40S ribosome biogen-
esis, this led to the translational upregulation of 50 terminal oligo-
pyrimidine tract (TOP) mRNAs, including RPL11 (Fumagalli et al.,
2009). Initially, we reasoned this effect was triggered by the
continued synthesis of 60S ribosomes and the resulting
consumption of nascent RPL11 into 60S ribosomal subunits
(Fumagalli et al., 2009). However, we recently found that code-
pletion of both a 60S and 40S ribosomal protein, a condition
where competition for RPL11 would be eliminated, still led to
the translational upregulation of RPL11 mRNA (Fumagalli et al.,
2012). These findings argue that although the two mechanisms
exploited the same molecular components to inhibit Hdm2,
they were differentially regulated. Moreover, both responses
were insulated from one another, as the impairment of both sub-
units led to an additive effect on p53 induction and amore severe
cell-cycle arrest (Fumagalli et al., 2012). The questions that arise
from these studies are: what is sensed as damage in each case
and what are the mechanisms by which these responses lead to
the induction of p53? It was initially argued to be a passive
response associated with disruption of the nucleolus, based
largely from studies employing actinomycin D (Rubbi and Milner,2003). However, this does not seem to be the case; instead, it
appears that activation of p53 is associated with the disruption
of nascent ribosome biogenesis (Fumagalli et al., 2009). Interest-
ingly, the studies presented here suggest that it is the nascent
RPL5/RPL11/5S rRNA complex that elicits this response,
consistent with the recent findings of Bursac et al. implicating
newly synthesized RPL5 and RPL11 in this response (Bursac
et al., 2012). At this stage, it will be important to isolate the pre-
sumedRPL5/RPL11/5S rRNA complex induced by impaired 60S
and 40S ribosome biogenesis to determine whether there are
differences in their molecular makeup. Likewise, the mecha-
nisms involved in upregulation of 50TOP translation should
shed insight into the underlying mechanisms that signal the
execution of the response to impaired ribosome biogenesis.
The pathological consequences of insufficient RPs were first
recognized in DBA and 5q syndrome, diseases characterized
by severe macrocytic anemia and bone marrow failure (Fuma-
galli and Thomas, 2011). In mouse models of 5q syndrome
and DBA, the anemic phenotype can be largely reversed by
depletion of p53 (Jones et al., 2008). Studies in mice further
demonstrate that not all ribosome protein insufficiencies present
with equivalent phenotypes. For example, heterozygous deletion
of RPS6 caused embryonic lethality that was delayed, but not
rescued, by loss of p53 (Panic et al., 2006), which is consistent
with the fact that mutations in RPS6 have not been reported in
DBA patients. Even so, conditional depletion of RPS6 in juvenile
or adult mice leads to a very similar DBA phenotype (McGowan
et al., 2011), which is rescued by loss of p53. Thus, the lesion in
ribosome biogenesis is not the apparent cause of the disease but
rather activation of p53 (Fumagalli and Thomas, 2011). This rai-
ses questions regarding the role of a RPL5/RPL11/5S rRNA
complex in DBA and 5q syndrome, as hypomorphic mutations
in RPL5 and RPL11 have been identified in DBA (Gazda et al.,
2008). Interestingly, the congenital phenotypes caused by muta-
tions in RPL5 and RPL11 are generally more severe than those
observed with other RP gene mutations (Gazda et al., 2008). In
developing better therapeutic approaches, it will be critical to
determine whether the RPL5/RPL11/5S rRNA complex is impli-
cated in this response or whether instead p53 stabilization is
mediated by a distinct mechanism.
DBA as well as 5q syndrome patients have an increased risk
of developing cancer, including acute myeloid leukemia, with a
cumulative incidence of 20% by the age of 46 (Vlachos et al.,
2012). This is consistent with findings in both Drosophila and
zebrafish that hypomorphic alleles of RP genes act as haploid-
insufficient tumor suppressors (Amsterdam et al., 2004; Stewart
and Denell, 1993). In zebrafish, 11 of the 12 lines developed
malignant peripheral nerve sheath tumors (MPNST), each
heterozygous for a distinct RP mutation (Amsterdam et al.,
2004). Interestingly, in each case, the zebrafish with hypomor-
phic mutation of an RP gene that also developed MPNSTs
displayed reduced levels of p53 (MacInnes et al., 2008). Ques-
tions that arise from this observation are, do cancers of DBA
and 5q syndrome patients result from reduced p53 levels? If
so, what is the underlying mechanism that allows such tumors
to become aggressive if translational capacity is impaired?
One of the mechanisms attributed to p53’s role as a tumor
suppressor is through repression of the transcription of theCell Reports 4, 87–98, July 11, 2013 ª2013 The Authors 95
proto-oncogene c-Myc, through either direct transcriptional
repression (Ho et al., 2005) or induction of miR145 (Sachdeva
et al., 2009). It has been known for some time that a primary func-
tion of c-Myc is the transcriptional upregulation of ribosomal
components mediated through all three RNA polymerases (van
Riggelen et al., 2010). Thus, in a tumor setting, a hypomorphic
allele of an RP gene may not be limiting if c-Myc is hyperacti-
vated and the other allele is intact. Interestingly, recent studies
suggest that p53 suppresses c-Myc-driven tumors through an
RPL5/RPL11 checkpoint (Bywater et al., 2012; Macias et al.,
2010) and that RPL11 can suppress the expression of c-Myc
through a negative feedback loop that controls c-Myc mRNA
stability (Challagundla et al., 2011; Dai et al., 2007). It will be of
clinical relevance to determine whether these effects are inde-
pendently regulated by RPL11, RPL5, and 5S rRNA or by an
RPL5/RPL11/5S rRNA complex.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfections, and Drug Treatments
U2 OS cells and p53/MDM2 double-knockout (DKO) MEFs were cultured and
maintained as previously described (Fumagalli et al., 2009). Lipofectamine
RNAiMAX (Invitrogen) and Opti-MEM medium (Invitrogen) were used accord-
ing to the manufacturer’s protocol for siRNA transfections. The siRNA se-
quences for 5S rRNA, RPL5, and RPL11 have been previously described
(Fumagalli et al., 2009, 2012; Li and Gu, 2011); siRNA sequences for GTF3A,
POLR1A, hRRS1, and BXDC1 are listed in Table S1. Nonsilencing siRNA
(QIAGEN) was used as a control and for normalization. Plasmids encoding
HA-Hdm4, HA-Hdm2, FLAG-L11, and FLAG-L5 have been previously
described (Dai et al., 2007; Dai and Lu, 2004). MEFs were transfected with
plasmids using the Amaxa Nucleofector (Lonza) 24 hr before harvest. Actino-
mycin D (BioVision Technologies) was used at a final concentration of 5 ng/ml.
RNA Extraction, Reverse Transcription, Real-Time PCR, and
Northern Blot
Cells were harvested and total RNA was extracted with TRI Reagent (Molecu-
lar Research Center) according to the manufacturer’s instructions. Whole-cell
RNA was reverse transcribed using the Superscript III kit (Invitrogen). Real-
time PCR was performed on an ABI 7900HT (Applied Biosystems) using the
2-DDCT method for analysis (Livak and Schmittgen, 2001). The mean DCT
value of the control sample was used in each experiment to calculate the
DDCT value of sample replicates. Primer sequences used for SYBR green
real-time PCR analysis of b-actin, 5S rRNA, pre-tRNAs, RPL11, and RPL5
have been previously described (Fumagalli et al., 2009, 2012; Livak and
Schmittgen, 2001; Shor et al., 2010; Winter et al., 2000) Other primers (listed
in Table S2) were designed using the IDT PrimerQuest online tool (http://eu.
idtdna.com/SCITOOLS/Applications/PrimerQuest/Default.aspx). Northern blot
analysis was performed as previously described (Fumagalli et al., 2009) with
a probe specific for human ITS2 (Table S2).
Autoradiographic Analysis of rRNA Processing and 5S rRNA
Synthesis
To evaluate rRNA processing, newly synthesized RNA was labeled by incu-
bating the cells for 45min in medium containing 1.2 mCi [5,6-3H]-uridine (Perkin
Elmer) per ml. Pulsed-labeled cells were then washed into medium containing
1mMnonradioactive uridine (Sigma) and incubated for 4 hr at 37C in 5%CO2.
Following extraction, 1 mg of total RNA was size-separated by electrophoresis
on a 1% agarose-formaldehyde gel. To evaluate 5S rRNA synthesis, total RNA
was extracted following the 2 hr pulse and 2 mg of each RNA sample was elec-
trophoresed on a TBE-urea 10% polyacrylamide gel. Following electropho-
resis, the RNA in both cases was transferred to Hybond N+ membrane
(Amersham Biosciences) and the blots were sprayed with En3Hancer (Perkin
Elmer) and exposed to Kodak BioMax MS film (Kodak) at 80C for
autoradiography.96 Cell Reports 4, 87–98, July 11, 2013 ª2013 The AuthorsTotal Cellular Proteins Extraction and Western Blot Analysis
Total protein extraction and SDS-PAGE were performed as previously
described (Fumagalli et al., 2009). Briefly, cells were lysed on ice in extraction
buffer (50 mM Tris-HCl [pH 8], 250 mM NaCl, 1% Triton X-100, 0.25% sodium
deoxycholate, 0.05% SDS, 1 mM dithiothreitol [DTT], and protease inhibitors
cocktail [Roche]). The lysates were cleared by centrifugation and quantified
by Bradford protein assay (Bio-Rad). Primary antibodies for western blotting
were as follows: mouse monoclonal anti-FLAG (M2; Sigma-Aldrich), anti-p21
(SX118; BD Pharmingen), anti-Hdm2 (SMP14; Santa Cruz Biotechnology),
anti-p53 (BP53-12; Sigma-Aldrich), anti-rpL11 (3A4A7; Invitrogen), anti-
rpL36a (43-A; Santa Cruz), rabbit polyclonal anti-p53 (FL393; Santa Cruz),
anti-Hdm4 (Bethyl Laboratories), anti-b-actin (Sigma-Aldrich), and anti-rpL5
(a gift from H. Lu and M.S. Dai).
Immunoprecipitation
For immunoprecipitation, cells were lysed on ice in immunoprecipitation buffer
(25 mM Tris HCl [pH 7.5], 150 mM KCl, 5 mM MgCl2, 1 mM EGTA, 1mM DTT,
10% glycerol, 0.8% Igepal/NP40, and protease inhibitors cocktail [Roche]).
The lysates were cleared by centrifugation and quantified by Bradford protein
assay (Bio-Rad). Ribosomes were pelleted by ultracentrifugation (200,000 3 g
for 2 hr at 4C) to obtain postribosomal supernatants. Equivalent amounts of
protein (1 mg for each sample) were incubated at 4C with rotation overnight
in immunoprecipitation buffer with anti-MDM2 (H-221; Santa Cruz), anti-HA
(12CA5; prepared from a hybridoma), or anti-FLAG (M2; Sigma-Aldrich). Protein
A- or G-coated agarose beads (Santa Cruz) were added to the extracts and
mixedby rotation foranadditional 2hrat4C.Thebeadswerewashed four times
with immunoprecipitation buffer, with each sample being divided into two ali-
quots before the fourth wash. Following final centrifugation, one aliquot was re-
suspended in protein loading buffer for western blot analysis; the other aliquot
was resuspended in TRI reagent (Molecular Research Center) to recover immu-
noprecipitated RNA for 5S rRNA real time PCR analysis, as described above.
Polysome Profiles and Cell-Cycle Analysis
Preparation of extracts for polysome profiles and sucrose gradient analysis
were as described previously (Fumagalli et al., 2009), except that gradients
were analyzed on a Gradient Station (Biocomp Instruments) equipped with
an EM-1 Econo UV monitor (Bio-Rad). Cell-cycle analyses were performed
as described previously (Fumagalli et al., 2009).
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